Evidence map›Paper›PMID 28717689›Full record

ArticleJournal of global oncology2016

Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model.

Cyprien Shyirambere, Mary Jue Xu, Shekinah Nefreteri Elmore, Temidayo Fadelu, Leana May, Neo Tapela, Denis Gilbert Umuhizi, Frank Regis Uwizeye, Caitlin Driscoll, Clemence Muhayimana and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Cyprien Shyirambere, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Mary Jue Xu, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Shekinah Nefreteri Elmore, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Temidayo Fadelu, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Leana May, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Neo Tapela, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Denis Gilbert Umuhizi, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Frank Regis Uwizeye, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Caitlin Driscoll, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Clemence Muhayimana, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Vedaste Hategekimana, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Fidel Rubagumya, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Ignace Nzayisenga, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Lawrence N Shulman, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Tharcisse Mpunga, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Leslie E Lehmann, , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY.
Partners In Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSuccess in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internists and pediatricians, and data collection structured for monitoring and evaluation. Here, we report clinical outcomes and protocol compliance for patients with nephroblastoma evaluated at Butaro Cancer Center of Excellence in Rwanda. PATIENTS AND

methodsThis retrospective study reports the care of 53 patients evaluated between July 1, 2012, and June 30, 2014. Patients receiving less than half of their chemotherapy at Butaro Cancer Center of Excellence were excluded.

resultsOf the 53 patients included, 9.4% had stage I, 13.2% had stage II, 24.5% had stage III, 26.4% had stage IV, and 5.7% had stage V disease; the remaining 20.8% had unknown stage disease from inadequate work-up or unavailable surgical report. The incidence of neutropenia increased with treatment progression, and the greatest proportion of delays occurred during the surgical referral phase. At the end of the study period, 32.1% of patients (n = 17) remained alive after treatment; 24.5% (n = 13) remained alive while continuing treatment, including one patient with recurrent disease; 30.2% (n = 16) died; and 13.2% (n = 7) were lost to follow-up.

conclusionOur findings confirm that nephroblastoma can be effectively treated in resource-constrained settings. Using an approach in which chemotherapy is delivered at a rural-based center by nononcologists and data are used for routine evaluation, care can be delivered in safe, novel ways. Protocol modifications to mitigate chemotherapy toxicities and strong communication between the multidisciplinary team members will likely minimize delays and further improve outcomes in similar settings.

Identifiers

PMID28717689
PMCPMC5495448
OpenAlexW2307653175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.